WallStSmart

Southern Copper Corporation (SCCO)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Southern Copper Corporation generates 28462% more annual revenue ($15.79B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 35.9%. SCCO trades at a lower P/E of 27.6x. SCCO earns a higher WallStSmart Score of 65/100 (B-).

SCCO

Strong Buy

65

out of 100

Grade: B-

Growth: 9.3Profit: 10.0Value: 4.3Quality: 8.0
Piotroski: 5/9Altman Z: 3.11

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.5Value: 5.3Quality: 7.5
Piotroski: 5/9Altman Z: 1.19

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SCCO6 strengths · Avg: 10.0/10
Return on EquityProfitability
44.9%10/10

Every $100 of equity generates 45 in profit

Profit MarginProfitability
35.9%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
61.2%10/10

Strong operational efficiency at 61.2%

Revenue GrowthGrowth
40.6%10/10

Revenue surging 40.6% year-over-year

EPS GrowthGrowth
71.6%10/10

Earnings expanding 71.6% YoY

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

VMET6 strengths · Avg: 9.5/10
Profit MarginProfitability
58.4%10/10

Keeps 58 of every $100 in revenue as profit

Operating MarginProfitability
90.6%10/10

Strong operational efficiency at 90.6%

Revenue GrowthGrowth
594.0%10/10

Revenue surging 594.0% year-over-year

EPS GrowthGrowth
573.0%10/10

Earnings expanding 573.0% YoY

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

SCCO3 concerns · Avg: 3.3/10
P/E RatioValuation
27.6x4/10

Moderate valuation

Price/BookValuation
13.4x4/10

Trading at 13.4x book value

PEG RatioValuation
5.412/10

Expensive relative to growth rate

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
28.7x4/10

Moderate valuation

Market CapQuality
$933.87M3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : SCCO

The strongest argument for SCCO centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.9% and operating margin at 61.2%. Revenue growth of 40.6% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.

Bear Case : SCCO

The primary concerns for SCCO are P/E Ratio, Price/Book, PEG Ratio.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VMET is growing revenue faster at 594.0% — sustainability is the question.

SCCO generates stronger free cash flow (1.5B), providing more financial flexibility.

Monitor COPPER industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SCCO scores higher overall (65/100 vs 60/100), backed by strong 35.9% margins and 40.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Southern Copper Corporation

BASIC MATERIALS · COPPER · USA

Southern Copper Corporation is engaged in the extraction, exploration, smelting and refining of copper and other minerals in Peru, Mexico, Argentina, Ecuador and Chile.

Visit Website →

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?